Table 6

Quantitative analysis of mRNA encoding SEREX-defined breast cancer antigens in normal and malignant breast tissue: Relation between mRNA level and immunogenicity.

Antigen Ratio of mRNA in breast cancer to mRNA in normal breast in patient # (+ indicates serum antibody reactivity1)
1 2 3 4 5 6 7 8 9 102
BR-41 0.01 0.19 0.04 0.26 0.38 0.11 0.10 0.86 0.03 0.07
BR-45/Kinesin 2 0.50 0.35 0.41 0.25 0.34 0.27 0.43 0.85 0.23 0.57
BR-56/gC1Q 0.66 0.49 0.22 0.83 0.40 0.44 0.69 0.77 0.44 3.71 (+)
BR-57/Her2neu 0.30 1.17 2.48 2.18 1.43 65.49 107.39 5.91 0.44 1.81 (+)
BR-62 1.21 1.65 0.26 2.20 5.19 3.80 4.22 53.44 15.49 12.21 (+)
BR-63/TP D52 1.44 4.08 0.91 7.36 6.26 2.08 2.88 132.51 1.67 5.33 (+)
BR-75 2.27 0.34 0.48 0.59 0.43 0.34 0.37 0.78 0.36 1.06 (+)
BR-85 5.55 6.28 1.15 6.65 3.17 4.98 5.91 11.42 10.34 11.34 (+)
BR-96 0.53 1.09 0.45 0.65 0.39 0.33 0.56 0.81 0.31 1.26
BR-98/MAGE D 0.16 2.10 0.58 2.55 0.73 (+) 0.58 0.67 (+) 12.67 1.44 0.60

1Serum reactivity of patients # 1, 3, 5, 6, 7, 8, 9, and 10 assessed in the plaque assay. 2Patient # 10 referred to as allogeneic-1 in Table 1.